Bellerophon Therapeutics Stock News

Mesoblast was up on an IND approval targeting COVID-19. Crinetics announced positive trial data. Bellerophon announced earnings and program updates.

Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational New

BLPH was granted Emergency Expanded Access for INOpulse® for the treatment of COVID-19. The first COVID-19 patient who was treated has been discharged from the

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals ( INO – Research Report ), Intercept Pharma ( ICPT – Research Report ) and B

WARREN, N.J., April 06, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary.

I hope everyone’s had a good and, more importantly, safe week. It’s been a tough time, and we’re still in early innings. But if we stay safe, observe the social...

ION Geophysical (NYSE:IO) +120% on expecting big jump in Q1 revenues.Neptune Wellness Solutions (NASDAQ:NEPT) +47% on receiving health Canada authorization to commercialize natural, plant-based hand

Gainers ION Geophysical Corporation (NYSE: IO) shares rose 150% to $2.90 in pre-market trading after the company reported announces preliminary Q1 revenue in the range of $56...

Bellerophon currently intends to use the net proceeds from this offering for working capital, general corporate purposes, and other research and development efforts. The shares were offered by Beller

Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call a

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Bellerophon from this offering are expected to be $15.3 million, before deducting the placemen

Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric o

Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the I

The company’s nitric oxide delivery system has been granted FDA approval for compassionate use Continue reading...

Ventilators have become one of the most politicized and in-demand medical supplies as the number of COVID-19 cases in the U.S. grows and hospitals prepare...